

GLAXOSMITHKLINE PLC
Form 6-K
February 15, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 15 February 2019

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Conditional Share Awards

On 13 February 2019, the Company granted awards to the Executive Directors and Persons Discharging Managerial Responsibilities (PDMRs) listed below. The awards have been granted in accordance with the rules of the GlaxoSmithKline 2017 Deferred Annual Bonus Plan (DABP) which was approved by shareholders on 4 May 2017.

Executive Directors are required to defer 50% of any bonus earned into Ordinary Shares or ADSs for a period of three years. Other participants are required to defer 25% of any bonus earned into Ordinary Shares or ADSs for the same period.

With effect from 2018, DABP Matching Awards are no longer granted.

The awards of deferred shares (Deferred Bonus Awards) have been granted as conditional awards over ADSs for US participants and as nil-cost options over Ordinary Shares for all other participants.

The numbers of shares shown below are exclusive of dividend reinvestment that will accrue during the deferral period.

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status Chief Executive Officer
 - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.468	61,813
 - d) Aggregated information n/a (single transaction)
 - e) Date of the transaction 2019-02-13
 - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr H Barron
- b) Position/status Chief Scientific Officer and President, R&D
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

- b) Nature of the transaction Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

- | | | |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
| | \$40.53 | 37,120 |

- d) Aggregated information n/a (single transaction)

- e) Aggregated volume Price

- e) Date of the transaction 2019-02-13

- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R Connor
- b) Position/status President, Global Vaccines
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument
ISIN: GB0009252882

b) Nature of the transaction
Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

c) Price(s) and volume(s)
Price(s) Volume(s)
£15.468 16,223

d) Aggregated information
Aggregated volume Price
n/a (single transaction)

e) Date of the transaction
2019-02-13

f) Place of the transaction
n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name
Mr S Dingemans

b) Position/status
Chief Financial Officer

c) Initial notification/
amendment
Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
GlaxoSmithKline plc

b) LEI
5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument
ISIN: GB0009252882

b) Nature of the transaction
Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

c) Price(s) and volume(s)
Price(s) Volume(s)
£15.468 44,215

d) Aggregated information
Aggregated volume Price
n/a (single transaction)

e) Date of the transaction
2019-02-13

f) Place of the transaction
n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr J Ford
 - b) Position/status SVP & General Counsel
 - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument American Depository Shares ('ADSs')
ISIN: US37733W1053
 - b) Nature of the transaction Deferred Bonus Award of ADSs (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
\$40.53	3,202
 - d) Aggregated information n/a (single transaction)
 - e) Aggregated volume Price
 - f) Date of the transaction 2019-02-13
 - g) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr N Hirons
 - b) Position/status SVP, Global Ethics and Compliance
 - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction
 Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.468	6,801

d) Aggregated information
 Aggregated volume Price n/a (single transaction)

e) Date of the transaction 2019-02-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr L Miels
 b) Position/status President, Global Pharmaceuticals

c) Initial notification/
 amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument
 Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction
 Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.468	17,252

d) Aggregated information
 Aggregated volume Price n/a (single transaction)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- e) Date of the transaction 2019-02-13
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr B McNamara
- b) Position/status CEO, GSK Consumer Healthcare

- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument American Depositary Shares ('ADSs')

ISIN: US37733W1053

- b) Nature of the transaction Deferred Bonus Award of ADSs (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

- c) Price(s) and volume(s)

Price(s)	Volume(s)
\$40.53	6,251

- d) Aggregated information n/a (single transaction)
- e) Aggregated volume Price

- e) Date of the transaction 2019-02-13
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D Redfern
- b) Position/status Chief Strategy Officer

- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

c) Price(s) and volume(s) Price(s) Volume(s)
£15.468 15,331

d) Aggregated information n/a (single transaction)

Aggregated volume Price

e) Date of the transaction 2019-02-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R Simard

b) Position/status President, Pharmaceuticals Supply Chain

c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

c) Price(s) and volume(s) Price(s) Volume(s)

£15.468 5,540

- d) Aggregated information n/a (single transaction)
- e) Date of the transaction 2019-02-13
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas
- b) Position/status SVP, Human Resources
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

- c) Price(s) and volume(s) Price(s) Volume(s)
£15.468 13,098

- d) Aggregated information n/a (single transaction)
- e) Date of the transaction 2019-02-13
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr P Thomson
- b) Position/status President, Global Affairs
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

Ordinary shares of 25 pence
 each ('Ordinary Shares')

- a) Description of the financial instrument

ISIN: GB0009252882

- b) Nature of the transaction

Deferred Bonus Award of
 Ordinary Shares (under the
 GlaxoSmithKline 2017
 Deferred Annual Bonus
 Plan).

- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £15.468 | 8,972 |

- d) Aggregated information n/a (single transaction)
 Aggregated volume Price

- e) Date of the transaction 2019-02-13

- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms K Terrell
 b) Position/status Chief Digital & Technology
 Officer

- c) Initial notification/
 amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

- Details of the transaction(s): section to be repeated for (i) each type
 3. of instrument; (ii) each type of transaction; (iii) each date; and (iv)
 each place where transaction(s) has been conducted

American Depositary Shares
 ('ADSs')

- a) Description of the financial instrument

ISIN: US37733W1053

- b) Nature of the transaction

Deferred Bonus Award of
 ADSs (under the
 GlaxoSmithKline 2017
 Deferred Annual Bonus
 Plan).

	Price(s)	Volume(s)
c) Price(s) and volume(s)	\$40.53	7,899
d) Aggregated information Aggregated volume Price	n/a (single transaction)	
e) Date of the transaction	2019-02-13	
f) Place of the transaction	n/a	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: February 15, 2019

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc